OCUL Stock Analysis
OC
Uncovered
Ocular Therapeutix Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2014-07-25. Its first commercial drug product, DEXTENZA, developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocularitching associated with allergic conjunctivitis. Its earlier stage development assets include axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet AMD and other retinal diseases. Its travoprost intracameral implant (OTX-TIC) is under Phase II clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. The company has also completed Phase II clinical trials for cyclosporine intracanalicular insert (OTX-CSI) for the chronic treatment of dry eye disease and dexamethasone intracanalicular insert (OTX-DED) for the short-term treatment of the signs and symptoms of dry eye disease.